Human chymase is a serine proteinase that converts angiotensin (Ang) I to Ang II independent of angiotensin converting enzyme (ACE) in vitro. 
Introduction
Angiotensin I-converting enzyme (EC. 3.4.15.1) (ACE)1 is a zinc metallopeptidase that converts angiotensin (Ang) I to the vasopressor hormone Ang II (1) . ACE is present in plasma and in a number of tissues including blood vessels, kidney, heart, brain, and the adrenal gland (2) . ACE inhibitors are widely used in the treatment of hypertension and congestive heart failure. However, because Ang 11 is readily detected in plasma and tissues during ACE inhibitor therapy (3), some investigators have speculated that enzymes other than ACE are involved in the in vivo conversion of Ang I to Ang 11. For example, while examining the mechanism of action of Ang I in the dog aorta, Okunishi and co-workers (4) described both ACE-dependent and ACE-independent pathways of Ang II formation and indicated that a chymotrypsin-like enzyme was responsible for the Ang 11 formation that occurred in the presence of an ACE inhibitor. While studying the biochemical pathways of Ang II formation in the human heart, we observed that > 75% of the Ang 11-forming enzyme activity in human left ventricular tissue homogenates was not blocked by ACE inhibitors, but was blocked by serine proteinase inhibitors (5) . Our subsequent studies showed that the major Ang 11-forming serine proteinase from the human cardiac ventricles was a chymase. Human chymase, isolated from the heart and skin, is a glycoprotein with an apparent molecular weight of 30 kD by SDS-PAGE (6) . The human chymase gene and cDNA have recently been cloned (7) .
In situ hybridization and EM-immunocytochemical studies indicate that the mast cells and endothelial cells located within the human heart and its vessels are the site of chymase synthesis and storage (8) . A high level of chymase-like immunoreactivity is also localized to the cardiac interstitium and is likely associated with the interstitial extracellular matrix. In endothelial cells, chymase-like immunoreactivity is present in Weibel-Palade bodies. Recent studies suggest that secretion of the von-Willebrand factor stored in Weibel-Palade bodies is polarized, with the bulk of the secretion occurring in the basolateral direction (9) ; this would indicate that chymase is also released basolaterally. Consistent with this conjecture, EM-immunocytochemical studies indicate the presence of chymase-like immunoreactivity in the basolateral region of endothelial cells (8) . The immunocytochemical studies localizing chymase in the heart and vessels suggest that chymase plays a significant role in the interstitial formation of Ang 11. However, since mast cells are a major site of elaboration of chymase and since procurement of tissues could easily lead to mast cell degranulation and release of chymase, the possibility exists that in vivo chymase-dependent Ang II formation may be much less significant than that inferred from immunocytochemical studies or studies using isolated tissues.
In vivo pharmacological studies with Ang I in the presence of ACE inhibitors are one way to show the importance of an alternative pathway to ACE in Ang II formation. However, in these studies the possibility exists that even in the presence of high concentrations of ACE inhibitor, tissue ACE is not fully inhibited or that Ang I has intrinsic activity which allows a direct response without conversion in Ang II ( 10) . These studies also do not rule out the possibility that nonspecific carboxypeptidases rather than chymase can convert Ang I to Ang II.
In the present study we use a novel approach to show that chymase dependent Ang II formation can occur in conscious baboons. This approach uses a selective Ang II containing substrate, [Pro1 'DAla 12] Ang I, which is an inactive precursor that yields Ang II upon incubation with chymase, but not ACE (11, 12) . Extensive studies on the nature of the substrate binding site of human chymase has revealed key differences in the way human chymase binds Ang I prior to catalysis, compared to the interaction between ACE and Ang I. These differences were exploited to design [Pro "DAla'2] Ang I (11, 12) . A penultimate proline in peptides prevents ACE from cleaving a dipeptide from the COOH terminus [Pro 1DAla 12] Ang I and a carboxy-terminal DAla was added to prevent carboxypeptidases from making the penultimate proline into a COOH-terminal proline. Introducing Pro-DAla to the COOH terminus of Ang I also reduced the intrinsic activity of this Ang I analog for the Ang II receptor by a 100-fold compared to that of Ang I ( 12 (12) . Finally, in addition to the use of a chymase selective substrate, the use of a conscious baboon model for demonstrating chymase dependent Ang II formation circumvents potential problems related to the premature release of chymase from mast cells due to anesthesia or tissue handling. These studies provide evidence that chymase is functional in tissues of conscious baboons and represent an important step in understanding the role of the chymase-angiotensin system in primates.
Methods

Animal instrumentation
Nine adult baboons (7 males, 2 females), weighing to 16-27 kg were pre-instrumented for physiologic monitoring in the conscious state using methods previously described (13) . Briefly, after sedation with ketamine (10 mg/kg) and atropine (0.5 mg), the animals were intubated and anesthesia maintained with 1. Table II and hemodynamic and dimension variables from paired experiments with and without ACE blockade are compared as the percent change from baseline values in Table III Ang I-i.e., increases in LV systolic and diastolic pressure and the time constant of LV relaxation, decreases in LV fractional shortening and no changes in either heart rate or peak positive LV dP/dt. Direct positive inotropic effects (i.e., increases in LV [+] dP/dt and shortening) were not observed.
Tissue distribution of chymase-like activity. A summary of chymase-like activity in several tissues from normal and renal artery-clipped baboons is presented in Table V . Additional baboon tissues were made available from an unrelated study. Chymase-like activity was widely distributed in normal and hypertensive baboons. The highest levels of chymase-like activity were observed in the spleen and lungs; most other tissues contained levels of chymase-like activity between 0.05 and 0.56% of that found in the spleen. Levels of chymase-like activity in cardiac ventricles and atria were intermediate (- 30 (Table V) .
Niscussion this study, we provide the first in vivo evidence of an ACEidependent pathway for Ang II production. Infusion of the ,ng I analog, [Pro''DAla12] Ang I, a selective and specific ibstrate for human chymase but not ACE, produced hemodyamic and left ventricular functional changes consistent with stemic arterial vasoconstriction; the latter is an action of Ang which is highly conserved in all mammals (17) . Although e demonstrated identical hemodynamic responses with [Pro " -Ala 12] Ang I infusion after pretreatment with captopril, we nnot be certain that plasma ACE was suppressed entirely or at tissue ACE was blocked. However, the absence of any tenuation of the hemodynamic changes by ACE inhibition suggests that Ang II was generated at least in part, by an ACEindependent pathway. Thus, our data indicate that the hemodynamic effects we observed were the result of functional chymase-like activity in baboon tissues. This contention is supported by our additional finding in the postmortem studies; i.e., that chymase-like activity is present in several baboon tissues, including the heart and the aorta. To ensure that the hemodynamic effects we observed were not mediated by vasoactive peptides other than Ang II, the specific nonpeptide Ang H inhibitor, losartan, was given after a large bolus of [Pro"DAla2] Ang I. This caused a prompt and complete reversal of the hemodynamic and LV functional abnormalities. Moreover, [Pro11 DAla12] Ang I does not interact directly with the Ang II receptor (IC50 > 10 pM) (11) . Taken together, these data indicate that [Pro' DAla'2] Ang I-induced hemodynamic changes were caused by ACE-independent production of Ang II. Because of the unique substrate specificity-of human heart chymase (15) and the abundance of chymase-like activity in baboon cardiovascular tissues, we speculate that chymase is likely responsible for Ang II production in our study. However, because of the unavailability of a specific chymase inhibitor, we cannot explicitly rule out the contribution of other enzymes in the [Pro"-DAla'2] Ang I response. In addition to its potent vasoconstrictor effect, Ang 11 modulates directly and indirectly cardiac rate, contractility and myocyte hypertrophy and proliferation. Ang II has a direct positive inotropic effect in some, but not all, isolated heart preparations (18) (19) (20) (21) (22) (23) (24) in which indirect Ang II sympathetic facilitation was excluded. For example, a positive inotropic effect has been demonstrated in isolated hearts from dogs (19, 20) , cats (21) , rabbits (22), chickens (22), and humans (23), but not in guinea pigs or adult rats (24) . In contrast, a positive inotropic effect has been difficult to demonstrate in the intact organism (25, 26 heart, direct inotropic effects of angiotensin II required a dose 60 times greater than the dose that caused sympathetic effects (20) . Finally, the inotropic response of isolated muscle is het- (27) . Thus, it is possible that dosage, experimental preparation and species and regional differences explain the lack of a positive inotropic effect in our study. Ang II has complex effects on heart rate. In addition to a direct positive chronotropic effect (19) , Ang 11 increases heart rate by facilitating sympathetic neurohormonal activity and by a central reduction of vagal tone; baroreceptor-mediated slowing of the heart rate in response to Ang 11-provoked hypertension opposes these effects (18) . Despite a striking elevation of LV systolic pressure, we observed no significant changes in the heart rate. Thus our data suggest a concomitant direct positive chronotropic effect of Ang 11 in the intact animal. Since our animals were not vagally blocked, a central parasympathetic effect cannot be excluded. Interestingly, heart rate was unchanged when either [Pro "DAla12] Ang I or Ang II was infused directly into the left coronary artery; the absence of a chronotropic response to left coronary injection may reflect the right coronary arterial supply of the Ang 11 receptor-rich sinus node (28) or a dose-related effect.
Ang 11 effects on diastolic LV function have received scant attention. In isolated myocytes and isolated human atrial trabeculae, Ang H produced a dose-dependent delay in relaxation (23, 29) . In isolated, perfused rat hearts, Ang II activation (Ang I infusion) caused a dose-dependent increase in isovolumic LV diastolic pressure in rats with experimental pressure overload left ventricular hypertrophy, but not in sham operated rats (30) . In the present study, the time constant of left ventricular relaxation was increased significantly by the large bolus of [Pro "-DAla 12] Ang I, suggesting impaired left ventricular diastolic function. However, this may reflect the large afterload stress produced by Ang 11-mediated vasoconstriction. In addition, the small, but significant increase in the time constant of isovolumic LV relaxation after the 100 ,ug intracoronary bolus may reflect the sensitivity of this index to changes in afterload in anesthetized animals (31) . By contrast, low (nonsystemic) doses of intracoronary [Pro'1DAla'2 I Ang I produced no effect on diastolic function as measured by the time constant of LV relaxation. Thus, our data provide additional evidence that Ang II does not have a significant direct effect on diastolic function in normal myocardium. However, the response to Ang II in hypertrophied primate myocardium is unknown. In aortic banded rats, ACE mRNA expression was increased in the hypertrophied left ventricle compared to sham controls (30) . In this regard it is interesting that we found reduced chymase activity in all cardiovascular tissues from hypertensive baboons, although statistical significance was achieved only with aortic tissue.
ACE inhibitors are used widely in the treatment of hypertension and heart failure. An alternative pathway for Ang II production, such as demonstrated in our study, represents a potential means by which tissues could escape from complete ACE inhibition of Ang II production. This may be particularly important in congestive heart failure. In the presence of ACE inhibitors, resulting high levels of Ang 1 (32) may be shunted to Ang II by chymase. It has been suggested that Ang II may have deleterious direct effects on the failing heart (33) . If so, then inhibition of chymase-like activity, in addition to ACE inhibition may prove more beneficial than ACE inhibitors alone in congestive heart failure.
There is also a complex relationship between ACE inhibition, Ang II levels, and clinical effects in systemic hypertension. During chronic therapy with ACE inhibition, plasma Ang II levels return to normal despite continued salutary vascular effects (3). The dissociation between plasma Ang II activity and the efficacy of ACE inhibitors in hypertension may relate in part, to the ability of ACE inhibitors to interact with a variety of substrates such as bradykinin, prostaglandin, substance P and enkephalins (34) . In a recent study, ACE inhibition in guinea pigs had an additive beneficial effect on blood pressure over either renin inhibition or Ang II receptor blockade that could not be accounted for by cyclooxygenase inhibition or bradykinin antagonism (35) . Thus, chronic suppression of Ang II production by inhibiting tissue chymase-like activity may prove a beneficial adjunct to ACE inhibition in the treatment of systemic hypertension.
In conclusion, 
